

## Challenges in Pharma trade

### What is the issue?

\n\n

The Indian pharmaceutical industry is facing challenges in both domestic as well as in international markets.

\n\n

### What is the model of Indian Pharma industries?

\n\n

\n

- India is the third largest supplier of the world's requirement of medicine.
- It capitalised on a strong domestic base in India through rapid product introductions, a kind regulatory and intellectual property system.
- Indian pharma companies chose pockets in Africa, Asia and the Middle East as natural expansion outposts.

\n

\n\n

### What are the challenges in Indian pharma trade?

\n\n

\n

- **Domestic**-Indian patients are paying high prices for drugs, due to fragmentation of distribution channels.
- The drug regulatory laws are not implemented in identical fashion across every state and city of the country.
- There are many ill-trained chemist all over the nation.
- **International**- US Supply channel consolidation has led to 90 per cent of the buying power concentration in three big companies, hindering trade of Indian companies.

\n

- The Food and Drug Administration along with increased scrutiny has been approving the backlog of drugs aggressively, leading to hyper-competition.  
\n
- Buyers have tightened the screws and are increasingly vigilant about even legitimate price increases.  
\n
- The combined effect has wiped out nearly 40 per cent of the core industry's market cap, destruction of over Rs 5 lakh crore.  
\n

\n\n

### **How the challenges can be addressed?**

\n\n

- The national regulator can engage to re-skill and train employees and hold them accountable to one common national standard.  
\n
- Beyond the core generics drugs companies should invest in diversified portfolio such as vaccines, animal health.  
\n
- The Indian pharma industry should focus on capital allocation choices and capability building.  
\n
- Three simple things innovation, calibrated diversification and consolidation must be carried out.  
\n
- The industry needs to diversify the geography risk beyond the US and India, invest in innovation beyond traditional generics and acquire more global scale.  
\n

\n\n

- India does not need more than 500 companies to have a reasonably competitive market, remaining should merge and acquire global scale.  
\n

\n\n

\n\n

**Source: Business Standard**

\n



**SHANKAR**  
**IAS PARLIAMENT**  
*Information is Empowering*